New pill shows promise for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC